GlobeNewswire·Feb 5, 2026, 6:00 AM ET

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

PBH

Prestige Consumer Healthcare reported Q3 2026 revenue of $283.4 million, exceeding its outlook despite a 2.4% year-over-year decline.
Diluted EPS for Q3 was $0.97, with Adjusted Diluted EPS at $1.14, compared to $1.22 in the prior year period.
The company repurchased approximately 0.8 million shares in Q3 for $45.8 million, utilizing strong free cash flow & low leverage.
The acquisition of eye care supplier Pillar5 Pharma, Inc. was successfully closed in December as expected.
Revenue declines in Q3 & the first nine months were primarily driven by limited supply capacity for Clear Eyes® in the Eye & Ear Care category.
Net debt as of December 31, 2025, stood at approximately $1.0 billion, resulting in a leverage ratio of 2.6x.
First nine months 2026 net income totaled $136.4 million, while Adjusted Net Income reached $154.8 million.
The company narrowed its Fiscal 2026 revenue outlook to approximately $1.1 billion due to a challenging consumer environment.
Fiscal 2026 Adjusted Diluted EPS outlook remains at approximately $4.54, with Free Cash Flow guidance maintained at $245 million or higher.
North American OTC Healthcare segment revenue decreased 1.3% in Q3 to $235.7 million, while International OTC Healthcare revenue fell to $47.7 million.
Operating cash flow for the first nine months was $214.8 million, with Non-GAAP Free Cash Flow at $208.8 million.
Non-GAAP Adjusted Net Income for the first nine months included adjustments for a supplier loan write-off, Pillar5 acquisition costs, & discrete tax items.